TOP > クイック検索 > 外国特許検索 > POLYMERIZED PEPTIDE AND GEL HAVING COLLAGEN-LIKE STRUCTURE

POLYMERIZED PEPTIDE AND GEL HAVING COLLAGEN-LIKE STRUCTURE

外国特許コード F170008954
整理番号 (S2015-1677-N0)
掲載日 2017年2月16日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP068667
国際公開番号 WO 2016208673
国際出願日 平成28年6月23日(2016.6.23)
国際公開日 平成28年12月29日(2016.12.29)
優先権データ
  • 特願2015-127450 (2015.6.25) JP
発明の名称 (英語) POLYMERIZED PEPTIDE AND GEL HAVING COLLAGEN-LIKE STRUCTURE
発明の概要(英語) Although collagen is useful as a medicinal material, its use in humans involves the risks of allergy and zoonoses. Therefore, artificial collagens and the like are being studied as medicinal materials. However, typical artificial collagens cannot be considered completely sufficient, given their lack of physical strength, being denatured by heat, inability to be processed into a sheet, and the like, and thus being problematic in terms of practicality. In the present invention, a collagen-like peptide having a triple helical structure comprising triple strands of peptide chains including a plurality of cysteine (cys) residues is oxidized and cross-linked to prepare a polymerized peptide. This polymerized peptide may be processed into and used as a hydrogel and a thin-film sheet. In addition, by inserting a functional amino acid sequence present in biomacromolecules, particular physiological functions such as cell adhesiveness may be obtained. Further, the present invention provides: methods for preparing the polymerized peptide and the like; and uses thereof as compositions in cell cultures, wound coverings, regenerative medicinal materials, and research materials and the like by using the same.
特許請求の範囲(英語) [claim1]
1. Being polymerization peptide,
It repeats 3 these chain peptides which possess triple helical structure and it possesses as the unit, is polymerized with oxidation building a bridge,
Each peptide chain which forms aforementioned 3 these chain peptides also or being identical it may differ mutually,
Each peptide chain, from each of the peptide basis and amino end and the [karubokishi] end which for triple spiral formation at least possess the repetition structure of 5 times - (Xaa-Yaa-Gly) - as a basic unit at least the cystein of 2 residues (Cys) features that it possesses the peptide basis for crosslinking which includes the residue within 10 residues, polymerization peptide.
[As for Xaa and Yaa, becoming independent respectively, the proline (Pro or P) the residue, the hydroxy proline (Hyp or O) the residue, the arginine (Arg or R) the residue, the ricin (Lys or K) the residue, the valine (Val or V) residue, the leucine (Leu or L) the residue, isoleucine (Ile or I) residue, ceric (Ser or S) residue and [toreonin] (Thr or T) the residue and the alanine (Ala or A) the residue, glycine (Gly or G) the residue and the phenylalanine (Phe or F) the residue and the methionine (Met or M) residue, glutamic acid (Glu or E) The residue and aspartic acid (Asp or D) the residue, the asparagine (Asn or N) the residue, the glutamine (Gln or Q) the residue, histidine (His or H) residue and [toriputohuan] (Trp or W) the residue or thyrosin (Tyr or Y) it is selected from the residue, the proline residue may be decorated with the amino group or fluorine atom, in Xaa rank and Yaa rank making use of the [N]-isobuchiru basic glycine residue is good.]
[claim2]
2. Being the polymerization peptide of statement in claim 1,
As for the aforementioned peptide chain,
(i) At least the peptide basis for one aforementioned triple spiral formation the peptide chain which at least consists of the peptide basis for one crosslinking,
(ii) At least the peptide basis for one aforementioned triple spiral formation the peptide chain which at least includes one which at least possesses the peptide basis for one crosslinking, and the motif which possesses physiological activity peptide basis, and,
(iii) At least through linker to the side chain of the peptide basis for one aforementioned triple spiral formation and the peptide basis, and the amino acid residue for crosslinking, the peptide chain which at least includes one which makes the motif connect which possesses physiological activity peptide basis
It features that at least it is one which is selected from the group which consists of, polymerization peptide.
[claim3]
3. Being the polymerization peptide of statement in claim 2,
It features that it is produced combining 2 types or more of motif which possesses the aforementioned physiological activity, copolymerization peptide.
[claim4]
4. Being production method of the polymerization peptide of statement in claim 1,
(Xaa-Yaa-Gly) The process which melts the peptide chain which is possible to differ mutually possesses the repetition structure of 5 times at least as a basic unit, from each of amino end and [karubokishi] end at least within 10 residues the cystein of 2 residues (Cys) it includes the residue in the solvent,
The process which forms 3 these chain peptides which possess the triple helical structure which consists of 3 of the aforementioned peptides with self-assembly,
The process where it possesses it repeats said 3 these chain peptides and makes polymerize with oxidation building a bridge as the unit,
It features that it includes, production method.
[As for Xaa and Yaa, becoming independent respectively, the proline (Pro or P) the residue, the hydroxy proline (Hyp or O) the residue, the arginine (Arg or R) the residue, the ricin (Lys or K) the residue, the valine (Val or V) residue, the leucine (Leu or L) the residue, isoleucine (Ile or I) residue, ceric (Ser or S) residue and [toreonin] (Thr or T) the residue and the alanine (Ala or A) the residue, glycine (Gly or G) the residue and the phenylalanine (Phe or F) the residue and the methionine (Met or M) residue, glutamic acid (Glu or E) The residue and aspartic acid (Asp or D) the residue, the asparagine (Asn or N) the residue, the glutamine (Gln or Q) the residue, histidine (His or H) residue and [toriputohuan] (Trp or W) the residue or thyrosin (Tyr or Y) it is selected from the residue, the proline residue may be decorated with the amino group or fluorine atom, in Xaa rank and Yaa rank making use of the [N]-isobuchiru basic glycine residue is good.]
[claim5]
5. Either of the claim 1-3 it features that at least 1 kinds of polymerization peptide of statement are included in 1 sections, the gelatinizer.
[claim6]
6. Either of the claim 1-3 it features that at least 1 kinds of polymerization peptide of statement are included in 1 sections, the gel.
[claim7]
7. Either of the claim 1-3 the polymerization peptide which at least combines 3 these chain peptides of 2 kinds to 1 sections 3 these chain peptides of statement as a polymerization unit, it features that it includes, in claim 6 the gel of statement.
[claim8]
8. The cystein residue it features that at least 1 kinds of 3 these chain peptides which are not included furthermore are included, in claim 6 or 7 the gel of statement.
[claim9]
9. Either of the claim 6-8 being the gel of statement in 1 sections,
The gel, is the hydrogel, it features that it is used as the backing material in order to culture the selective cell, the gel.
[claim10]
10. Either of the claim 6-9 making the gel of statement 1 sections dry, it is produced, the polymerization peptide thin film.
[claim11]
11. Either of the claim 6-9 it features that the polymerization peptide thin film of statement is included in the gel or claim 10 of statement in 1 sections, the playback medical material.
[claim12]
12. Being the playback medical material of statement in claim 11,
It features that it is the composition for healing of wound promotion, the playback medical material.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • WASEDA UNIVERSITY
  • KOLA-GEN PHARMA INC.
  • 発明者(英語)
  • KOIDE TAKAKI
  • ICHISE SHINICHIRO
  • TAKEUCHI SHUNGO
  • NOSE HIROSHI
国際特許分類(IPC)
指定国 (WO2016208673)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
技術導入、技術提携、実用化開発(受託研究・共同研究等)のご相談を承っております。お気軽にご連絡ください。

PAGE TOP

close
close
close
close
close
close